A research associate works at the Moderna Therapeutics Inc. lab in Cambridge, Massachusetts, US | Bloomberg
A research associate works at the Moderna Therapeutics Inc. lab in Cambridge, Massachusetts, US | Bloomberg
Text Size:

New York: Researchers, led by an Indian scientist, have developed a cheap, electricity-free centrifuge to separate components in patient saliva samples for the detection of the novel coronavirus, an innovation that may increase accessibility of COVID-19 diagnostics in poor regions of the world.

According to the scientists, including Manu Prakash from Stanford University in the US, the ‘Handyfuge’ device spins tubes containing patient saliva at very high speeds, enough to separate the virus genome from other components in the sample, without needing electricity.

They said the cheap centrifuge, described in a yet-to-be peer-reviewed study published in the platform medRxiv, can be assembled using readily available components for a cost less than five USD per unit.

It can allow clinicians and scientists to carry out a quick and cheap diagnostic technique called the LAMP assay to detect the presence of the novel coronavirus genome in patient saliva samples, the scientists noted.

The LAMP protocol, according to Prakash and his team, “has the benefits of being simple, requiring no specialised equipment, rapid, requiring less than an hour from sample collection to readout, and cheap, costing around one dollar per reaction using commercial reagents.”

While the assay has several merits, the Stanford scientists said there could be a variability in output in diagnostic methods based on viral genome detection in saliva samples.

They explained that this is due to the saliva containing substances which can inhibit diagnostic reagents.

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.


“Centrifugation to separate the reaction inhibitors from inactivated sample was shown to be an effective way to ensure reliable LAMP amplification,” the scientists wrote in the study.

However, they said a centrifuge capable of safely achieving the necessary speeds of 2000 rotations per minute (RPM), for several minutes, costs hundreds of dollars, also requiring a power supply.

With Handyfuge, this hurdle can be over come, believes Prakash — a professor of Bioengineering at Stanford University, whose lab had earlier developed a cheap “origami microscope” called ‘Foldscope’.

The scientists explained that the novel device uses a mechanical strategy similar to that seen in ‘Dyno-torch’ flashlights to generate centrifugal force using kinetic input from the user.

Also read: We built a map on how coronavirus use human cells to spread. It is very similar to cancer

“The user repeatedly squeezes the handle to spin a small freewheel connected to a centrifuge spindle,” they wrote in the study.

After a designated amount of time, enough centrifugal force is applied to the sample-containing tubes, the scientists said, yielding a separated liquid layer that is free of chemicals that may inhibit the coronavirus genetic material, its RNA.

“This supernatant can then be reliably used for LAMP detection of SARS-CoV-2 or other viruses,” the researchers wrote.

According to the study, the Handyfuge-LAMP assay works based on protocol for the diagnostic method developed by scientists, Brian Rabe and Constance Cepko, from Harvard University in the US.

“This simple electricity-free LAMP protocol builds on fantastic work by Cepko lab at Harvard, but with a hand powered centrifuge to make this assay completely electricity free for resource constrained settings,” Prakash’s lab mentioned in a tweet.

“The advantage for handyfuge is increased stability and limited fluctuations in RPM and it matches covid test need,” the scientists noted on Twitter.

According to the scientists, the idea started from a flash light picked up from a toy store, which they hacked to build Handyfuge.

They said the Handyfuge, combined with the assay from Cepko and Rabe, works reliably in detecting synthetic COVID-19 RNA “down to 10-100 copies per microlitres in saliva.”

Commenting on the study, virologist Upasana Ray from the CSIR-Indian Institute of Chemical Biology in Kolkata said, “The mini-centrifuge is functionally equivalent to the ones used in molecular biology laboratories as bench top electricity driven ones.”

However, Ray said, non specific results may arise, such as when genetic sequences that have some degree of similarities — although otherwise might have different origins like host versus pathogen — could be detected as wrongly same.

Despite this problem, Ray added that a combination of the methods can potentially help in short listing “doubtful/suspected samples.”

These samples could then be validated further, she said.

“It’s like picking up a handful of green peas. Later you find some of them are rotten. Earlier part is LAMP, later part is a more specific PCR reaction or real time PCR reaction,” Ray explained.

“The authors have proposed the Handyfuge as a useful tool to clarify saliva samples. Saliva is an easily accessible totally noninvasive source. Thus taken together the proposed technology should be further validated on large sample sizes for a better understanding,” Ray added.

Using insulated coolers for reagent supply chain and delivery, the assay can be completed without the need for electricity “or any laboratory scale infrastructure,” the study noted.

However, to determine the effectiveness of the device as a point of care tool, the researchers said it will need to be validated using actual patient samples.

“We are currently preparing to test this protocol and Handyfuge in field settings,” they wrote in the study.

Also read: Don’t panic, this is what we know so far about new H1N1 strain with ‘pandemic potential’


Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

1 Comment Share Your Views


  1. All this test need to be fast-tracked in order to be useful. Our indigenous inventions of such kind only made headlines.
    FELUDA test kit developed by CSIR-IGIB kolkata was told to be a game changer and expected to arrive in may end. 2 months gone no news on same. similarly RT-LAMP test kit to be developed by CSIR- Jammu lab in collaboration with Reliance group . apart from this for antigen test we are dependent on Korean company.
    Our media is also not following up with CSIR on this tests only making, need some sincere journalism on these issues


Please enter your comment!
Please enter your name here